Anti-atherogenic effects of fibrates in type 2 diabetes
<p>Abstract</p> <p>Type 2 diabetes is an increasing cause of premature coronary heart disease. Several trials with lipid-modifying therapy have included sufficient numbers of diabetics to indicate that treatment of diabetic dyslipidaemia with either fibrates or statins reduces the...
Main Author: | Barter Philip |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2001-09-01
|
Series: | Current Controlled Trials in Cardiovascular Medicine |
Subjects: | |
Online Access: | http://cvm.controlled-trials.com/content/2/5/218 |
Similar Items
-
Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction
by: Tenenbaum Alexander, et al.
Published: (2012-10-01) -
Combined statin-fibrate therapy-induced rhabdomyolysis: Case report
by: Jozić Tanja L., et al.
Published: (2014-01-01) -
Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?
by: Tenenbaum Alexander, et al.
Published: (2004-12-01) -
Associação de medicamentos: estatinas e fibratos Combination of drugs: statins and fibrates
by: Hermes Toros Xavier
Published: (2005-10-01) -
Statin and fibrate associed myopathy: study of eight patients
by: Alzira A. Siqueira Carvalho, et al.
Published: (2004-06-01)